EPRX (Eupraxia Pharmaceuticals Inc. Common Stock) Stock Analysis - SEC Filings

Eupraxia Pharmaceuticals Inc. Common Stock (EPRX) is a publicly traded Healthcare sector company. As of May 21, 2026, EPRX trades at $6.37 with a market cap of $437.04M and a P/E ratio of 0.00. EPRX moved +1.27% today. Year to date, EPRX is -17.06%; over the trailing twelve months it is +63.34%. Its 52-week range spans $2.20 to $9.32. Analyst consensus is strong buy with an average price target of $14.80. Rallies surfaces EPRX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Where can I find EPRX SEC filings?

Rallies organizes EPRX SEC filing research, company disclosures, 10-K reports, 10-Q reports, and filing-driven context alongside market data, news, fundamentals, and AI research.

EPRX Key Metrics

Key financial metrics for EPRX
MetricValue
Price$6.37
Market Cap$437.04M
P/E Ratio0.00
EPS$0.00
Dividend Yield0.00%
52-Week High$9.32
52-Week Low$2.20
Volume0
Avg Volume0
Revenue (TTM)$0
Net Income$0
Gross Margin0.00%

Latest EPRX News

EPRX Analyst Consensus

6 analysts cover EPRX: 0 strong buy, 6 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $14.80.

Common questions about EPRX

Where can I find EPRX SEC filings?
Rallies organizes EPRX SEC filing research, company disclosures, 10-K reports, 10-Q reports, and filing-driven context alongside market data, news, fundamentals, and AI research.
Does Rallies show EPRX 10-K and 10-Q filings?
Rallies organizes EPRX SEC filing research, including 10-K reports, 10-Q reports, company disclosures, and filing-driven context when available.
Is EPRX research on Rallies investment advice?
No. Rallies provides research, data, and educational context for EPRX. It does not provide personalized investment advice.
EPRX

EPRX